the funniest thing about this pathetic valuation is that back when their cholesterol drug was going through preclinical studies market cap was a 70 million market cap even before GLP was passed on a potential market of 900 million dollars, which NYR was on par to FDA approved drugs as shown below:
Forward to now which NYR is showing potential to being superior to any other drug out there for a 4 billion dollar market. 20 million market cap absolutely laughable. Anyways I’m off for the weekend had my rant and the company has a ton of news flow coming up which only make the company stronger. Cheers mate have a good weekend
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)